AJTMH HINARI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 23(6), 1974, pp. 1120-1124
Copyright © 1974 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shepard, C. C.
Right arrow Articles by Fasal, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shepard, C. C.
Right arrow Articles by Fasal, P.

Further Experience with the Rapid Bactericidal Effect of Rifampin on Mycobacterium Leprae*

Charles C. Shepard, Louis Levy AND Paul Fasal
Center for Disease Control, Public Health Service, U.S. Department of Health, Education, and Welfare, Atlanta, Georgia 30333, and Leprosy Research Unit, Public Health Service Hospital, San Francisco, California 94118

The effect of rifampin therapy in leprosy was studied in two clinical short-term trials in which skin punch biopsy specimens were taken at regular intervals for the inoculation of mice in order to monitor the decrease in proportion of viable Mycobacterium leprae in the patients' lesions. In a trial of rifampin in a dosage of 600 mg daily, the bacterial viability fell to undetectable levels in the first specimen taken after the start of therapy (at 3–4 days in 4 patients, 7–8 days in 9, and 14 days in 2). Dapsone-treated controls required 20 to more than 112 days for the same change. In a trial of a single dose of 1,500 mg rifampin, the viability fell to undetectable levels in the first specimen taken after the start of therapy also (at 3–5 days in all 14 patients).

Accepted for publication May 11, 1974.


* Address reprint requests to: Charles C. Shepard, M.D., Leprosy and Rickettsial Diseases Section, Center for Disease Control, Atlanta, Georgia 30333.




This article has been cited by other articles:


Home page
 Am J Trop Med HygHome page
T. T. FAJARDO, R. S. GUINTO, R. V. CELLONA, R. M. ABALOS, E. C. DELA CRUZ, and R. H. GELBER
A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy.
Am J Trop Med Hyg, March 1, 2006; 74(3): 457 - 461.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
W. R. Levis, J. S. Schuman, S. M. Friedman, and S. A. Newfield
An Epidemiologic Evaluation of Leprosy in New York City
JAMA, June 18, 1982; 247(23): 3221 - 3226.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
G. A. FILICE and D. W. FRASER
Management of Household Contacts of Leprosy Patients
Ann Intern Med, April 1, 1978; 88(4): 538 - 542.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
W. E. SANDERS Jr.
Drugs Five Years Later: Rifampin
Ann Intern Med, July 1, 1976; 85(1): 82 - 86.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1974 by the American Society of Tropical Medicine and Hygiene.